

SAFETY DATA SHEET (SDS) — prepared in accordance with Regulation (EC) No 1907/2006 (REACH), Annex II, as amended by Regulation (EU) 2020/878.

⚠️ DRAFT — FOR RESEARCH USE ONLY (RUO). Adapted from authoritative published SDS data for the active substance Ivermectin (Cayman Chemical / ChemicalBook). Hazard data below describe the **active substance**; the final classification of this low-concentration tablet formulation must be confirmed by a competent person before issuance.

Safety Data Sheet — Ivermectin Tablets 5 mg × 30

Revision date: 2026-06-08 · Version: 1.0 (DRAFT) · Supersedes: none

SECTION 1: Identification

1.1. Product identifier

- Product name: **Ivermectin Tablets 5 mg × 30**
- Product code (SKU): LV5
- Active substance: **Ivermectin** (CAS 70288-86-7) — nominally 5 mg per tablet
- Pack size: 30 tablets

1.2. Relevant identified uses and uses advised against

- Identified use: **Strictly for laboratory research and analytical use only (Research Use Only, RUO).**
- Uses advised against: **NOT** for human or veterinary use, **NOT** for diagnostic or therapeutic use, **NOT** for food/feed. Not supplied as a medicinal product under Directive 2001/83/EC or as a veterinary medicinal product under Regulation (EU) 2019/6.

1.3. Supplier

- PeptidLabs · Registered company name & address: *[to be completed — operating legal entity]* · e-mail: info@peptidlabs.eu

1.4. Emergency telephone number

- +359 895 345 189 (*confirm 24/7 arrangement for EU placing on the market*)

SECTION 2: Hazards identification

The following classification is that of the **active substance Ivermectin**. This product is a **solid tablet containing ~5 mg ivermectin** (a low-concentration formulation); the classification of the finished tablet must be re-assessed under CLP mixture rules. Several hazards (notably aquatic and reproductive) may carry through even at low concentration — the data are presented conservatively.

2.1. Classification of the active substance (Regulation (EC) No 1272/2008 / CLP)

- Acute Tox. 2 (Oral) — **H300 Fatal if swallowed**
- Acute Tox. 3 (Dermal) — **H311 Toxic in contact with skin**
- Eye Irrit. 2 — **H319 Causes serious eye irritation**
- Carc. 2 — **H351 Suspected of causing cancer**
- Repr. 2 — **H361 Suspected of damaging fertility or the unborn child**
- STOT RE 2 — **H373 May cause damage to organs through prolonged or repeated exposure**
- Aquatic Acute 1 / Aquatic Chronic 1 — **H410 Very toxic to aquatic life with long lasting effects**

2.2. Label elements (active substance)

- Pictograms: **GHS06** (skull & crossbones), **GHS08** (health hazard), **GHS09** (environment)
- Signal word: **Danger**
- Precautionary statements (selection): P201, P264, P270, P273, P280, P301+P310, P305+P351+P338, P308+P313, P391, P405, P501

2.3. Other hazards

- **Research Use Only.** Not for human/animal exposure. Even in tablet form, handle with caution — treat as a substance of defined toxicity and follow good laboratory practice (GLP).

SECTION 3: Composition / information on ingredients

3.2. Mixtures — solid tablet; active substance disclosed below. Excipients are non-hazardous pharmaceutical tableting aids (full composition per manufacturer).

| Component | Identifier | Conc. | Classification |
|------------|--|-----------------|--|
| Ivermectin | CAS 70288-86-7 · EC 274-536-0 · C ₄₈ H ₇₄ O ₁₄ · MW 875.09 | ~5 mg/tablet | Acute Tox. 2; Acute Tox. 3; Carc. 2; Repr. 2; STOT RE 2; Aquatic Acute/Chronic 1 (H300, H311, H351, H361, H373, H410) |

SECTION 4: First-aid measures

- **Inhalation:** Move to fresh air. If unwell, obtain medical attention. Show this SDS.
- **Skin contact:** Remove contaminated clothing. Wash thoroughly with soap and water. If irritation persists, get medical advice.
- **Eye contact:** Rinse cautiously with water for several minutes; remove contact lenses if easy. Continue rinsing; seek medical attention.
- **Ingestion: Potentially fatal if swallowed.** Do NOT induce vomiting. Rinse mouth. **Seek immediate medical attention** and show the label/SDS.
- Most important symptoms: CNS effects (dizziness, ataxia, mydriasis) possible on significant exposure to the active. No specific antidote — treat symptomatically/supportively.

SECTION 5: Firefighting measures

- Suitable extinguishing media: water spray, alcohol-resistant foam, dry chemical, CO₂.
- Special hazards: combustion may release CO, CO₂, NO_x.
- Advice for firefighters: wear SCBA and full protective clothing. Prevent firefighting run-off from entering watercourses (**toxic to aquatic life**).

SECTION 6: Accidental release measures

- Personal precautions: wear PPE (Section 8); avoid dust.
- **Environmental precautions: prevent release to drains, soil and watercourses — H410.**
- Cleanup: collect tablets/fragments mechanically into a labelled container for disposal (Section 13).

SECTION 7: Handling and storage

- Handling: GLP; avoid ingestion, skin and eye contact; do not eat/drink/smoke; wash hands after handling.
- Storage: store in a cool, dry place at 15–25 °C, protected from light and moisture; keep tightly closed; keep away from foodstuffs and out of reach of unauthorised persons.

SECTION 8: Exposure controls / personal protection

- No EU OEL established for ivermectin. Use engineering controls (ventilation) to minimise exposure.
 - PPE: nitrile gloves (EN 374), safety glasses (EN 166), laboratory coat; respiratory protection if dust may be generated (EN 149 FFP2+).
-

SECTION 9: Physical and chemical properties

| Property | Value |
|-------------------------------|-------------------------------|
| Physical state | Solid (tablet) |
| Active substance appearance | White powder |
| Odour | Odourless / No data available |
| Water solubility (ivermectin) | ≤ 1.0% (poorly soluble) |
| Melting point (ivermectin) | ~155 °C (literature) |
| Molecular weight (ivermectin) | 875.09 g/mol |

SECTION 10: Stability and reactivity

- Stable under recommended storage. Avoid heat, moisture and light. Incompatible with strong oxidisers. Hazardous decomposition products: CO, CO₂, NO_x.

SECTION 11: Toxicological information

- **Acute oral toxicity (ivermectin): Category 2 — Fatal if swallowed (H300).** Acute dermal: Category 3 (H311).
- Eye irritation: Category 2 (H319). Carcinogenicity: suspected (Cat 2, H351). Reproductive toxicity: suspected (Cat 2, H361). STOT (repeated exposure): Category 2 (H373).
- Target effects of the active: neurotoxicity (GABA-mediated) at high doses.
- Note: values relate to the **pure active**; the tablet contains a small quantity per unit.

SECTION 12: Ecological information

- **12.1. Toxicity: Very toxic to aquatic life with long-lasting effects (H410).** Ivermectin is highly toxic to aquatic invertebrates and dung fauna.
- Persistence/bioaccumulation/mobility: refer to the active-substance dossier. **Do not release into the environment.**

SECTION 13: Disposal considerations

- Dispose of as hazardous laboratory/pharmaceutical waste in accordance with Directive 2008/98/EC and local regulation, via a licensed contractor. **Do not empty into drains** — aquatic hazard.

SECTION 14: Transport information

Pure ivermectin is a dangerous good:

| Field | Value (pure active) |
|------------------------|---|
| UN number | UN 2811 |
| Proper shipping name | TOXIC SOLID, ORGANIC, N.O.S. (Ivermectin) |
| Transport hazard class | 6.1 (Toxic) |
| Packing group | I |
| Marine pollutant | Yes (environmentally hazardous) |

Note: the finished **low-concentration tablet** (≈5 mg active) may fall **below the thresholds** that trigger UN 2811 / Class 6.1 classification, or may require Class 9 (UN 3077) if it remains an aquatic hazard above limits. **The transport classification of the finished product must be confirmed** by a dangerous-goods adviser before shipping.

SECTION 15: Regulatory information

- **CLP:** Ivermectin carries the hazard classification above (harmonised/self-classification — confirm Annex VI entry and the supplier's current SDS).
 - **REACH:** ivermectin is a known active substance; supplied here for research use only.
 - **⚠ RESEARCH USE ONLY (RUO).** Not a medicinal/veterinary product, not a food/feed. Must not be sold or used for human or animal consumption, diagnosis or therapy.
 - **Data source:** active-substance hazard data adapted from authoritative published SDS (Cayman Chemical SDS #35518; ChemicalBook, CAS 70288-86-7). Verify against the current supplier SDS before issuance.
-

SECTION 16: Other information

Abbreviations: see master glossary. **CMR** = Carcinogenic, Mutagenic, Reprotoxic. **OEL** = Occupational Exposure Limit.

Disclaimer: This SDS is a **draft** compiled to REACH Annex II structure, with active-substance hazard data adapted from authoritative published sources. The finished-product (tablet) classification, transport status and label must be **validated by a qualified competent person** before issuance. No liability is accepted for use outside the stated Research-Use-Only scope.

Draft document provided for informational purposes based on currently available data. Strictly for laboratory and in-vitro research use only.

Compliance draft for PeptidLabs · Revision 2026-06-08 · 1.0 (DRAFT)